COVID-19 vaccine heavyweight Pfizer (NYSE:PFE) will soon provide data related to the fourth dose of its COVID-19 vaccine, according to Bloomberg.
The company and its partner BioNTech (Nasdaq:BNTX) are also developing an omicron-specific version of the vaccine.
Pfizer CEO Dr. Albert Bourla said that the data to be shared with FDA involve the fourth dose of its original COVID-19 vaccine and a new formulation intended to protect against multiple SARS-CoV-2 variants.
Get the full story from our sister site, Drug Discovery & Development.